
Pioneering breakthrough treatments
for neurodegenerative diseases
A small molecule drug discovery company committed to defeating neurodegenerative diseases.
Brenig Therapeutics is redefining the frontier of aging science with a resolute focus on addressing neurodegeneration. Harnessing the power of advanced hybrid AI/ML platforms, biomarker-driven precision development, and synergistic partnerships, we are at the forefront of translating groundbreaking research into transformative therapies for a healthier, more resilient future.
Recent News
Recent News
July 23, 2024
Brenig Therapeutics Announces $65 Million Series A Financing to Advance Leading Pre-Clinical Parkinson's Disease Pipeline
November 26, 2024
Brenig Therapeutics Announces the Initiation of First-in-Human Clinical Trial of BT-267, a Best-in-Class LRRK2 Inhibitor for Parkinson's Disease
